Business
Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease
Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\n \n Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the \"Company\" \n or \"Kalytera\") is pleased to announce that the United States \n Patent and Trademark Office has issued a Notice of Allowance for US \n Patent Application 15/143,694 covering the use of cannabidiol (\"CBD\") \n in the treatment of graft versus host disease (\"GVHD\"). \n Securing a patent for this proprietary technology represents an \n important step forward for the Company in its work focused on the \n treatment of this serious and life-threatening disease.\n \n \n \"We are delighted to receive this Notice of Allowance from the USPTO\", \n said Robert Farrell, J.D., Kalytera's Chief Executive Officer. \"There \n are currently few options to treat persons with GVHD, a critically \n underserved market. The results of the previous four clinical studies \n that evaluated CBD in the prevention and treatment of GVHD were \n exceptional and unprecedented. Based on that data, we believe that our \n proprietary CBD based therapeutic may provide a major advance in the \n prevention and treatment of this disease, and we anticipate that we will \n also soon receive Notice of Allowance for our US Patent Application \n 14/787,515 that covers both the use of CBD in the prevention of graft \n versus host disease, and the treatment of graft versus host disease.” \n Kalytera has exclusive world-wide rights to the technology that is \n covered by both of these patents.\n \n \n GVHD is a multisystem disorder that is a common, life-threatening \n complication of hematopoietic stem cell transplant procedures. GVHD \n occurs when the transplanted donor cells attack the patient's organs, \n including the skin, gastrointestinal tract, liver, lungs and eyes. GVHD \n is associated with acute and chronic illness, infections, disability, \n reduced quality of life and death.\n \n \n Kalytera is currently advancing its Phase 2 clinical program evaluating \n the use of CBD in the prevention of GVHD. Completion of this Phase 2 \n program will take approximately eight months, and is required by the FDA \n prior to the initiation of a pivotal Phase 3 study. The Phase 2 program \n includes an open label, multicenter trial to evaluate the \n pharmacokinetic and safety profiles of multiple doses of CBD for the \n prevention of GVHD following allogeneic hematopoietic ...